← Leaderboards
Eric Eugene Kelley
University Of Pittsburgh At Pittsburgh
$2,318,020
Attributed
$4,069,060
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $882.4K · FY2013–24$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,069,060 · 4
By mechanism
R01$3,502,080 · 2
S10$304,020 · 1
P20$262,960 · 1
Top collaborators
- Nicholas Khoo4 shared
- Adam Carl Straub4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Thomas Gillette Gleason$6,192,678
- Adam Carl Straub$12,143,477
- Nicholas Khoo$680,523
- Heidi Marie Schmidt$105,102
- Robert M O'Doherty$9,250,192
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingGenerationsUric AcidInflammatoryEnzymesFebuxostatOverexpressionXanthine OxidaseReactive Oxygen SpeciesInjuryStressInflammationProductionPathway InteractionsPharmacologyHepaticPathogenicityObesityAllopurinolPlasmaHydrogen PeroxideCardiovascular DiseasesHypoxanthinesLink
Grant awards (10)
Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction$525,499
R01 · FY2024 · HL
Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction$536,222
R01 · FY2023 · HL
Targeting Uric Acid as a Therapeutic for NASH$336,143
R01 · FY2023 · DK
Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction$534,408
R01 · FY2022 · HL
Targeting Uric Acid as a Therapeutic for NASH$336,854
R01 · FY2022 · DK
Role of Xanthine Oxidase in Heme-induced Vascular Dysfunction$544,905
R01 · FY2021 · HL
Targeting Uric Acid as a Therapeutic for NASH$337,544
R01 · FY2021 · DK
Targeting Uric Acid as a Therapeutic for NASH$350,505
R01 · FY2020 · DK
Altering XOR Product Identity to Treat Ischemic Stroke$262,960
P20 · FY2020 · GM · contact PI
EPR Detection of Free Radicals in Vascular Disease: Bruker EMXPlus Spectrometer$304,020
S10 · FY2013 · OD · contact PI